Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

Trial Profile

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Interstitial lung diseases; Scleroderma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Feb 2016 Planned End Date changed from 1 Jun 2016 to 1 Aug 2017 as reported by Clinicaltrials.gov record.
    • 12 Feb 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Aug 2017 as reported by Clinicaltrials.gov record.
    • 12 Feb 2016 Status changed from not yet recruiting to recruiting as reported by Clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top